HighVista Strategies’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

HighVista Strategies’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,955	Closed	-$2.25M	–	162
2023 Q1	$2.25M	Buy	20,955 +1,679	+9%	+$193K	1.83%	20
2022 Q4	$2.12M	Buy	19,276 +11,445	+146%	+$742K	1.26%	24
2022 Q3	$462K	Sell	7,831 -2,951	-27%	-$135K	0.26%	83
2022 Q2	$304K	Buy	+10,782	New	+$313K	0.18%	93

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

HighVista Strategies's RXDX Position: Q2 2023 in Review

HighVista Strategies sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 20,955 shares — an estimated $2.25M sold.

HighVista Strategies first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $2.25M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

HighVista Strategies reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HighVista Strategies sold 20,955 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.25M.
HighVista Strategies first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
HighVista Strategies's Prometheus Biosciences, Inc. Common Stock position peaked at $2.25M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.